ClinicalTrials.gg
CompletedNCT06437626MIRUpdated Dec 30, 2025Results posted

Efficacy and Safety of Mexidol® in Stroke Therapy

A Phase 3 interventional study of Mexidol (Ethylmethylhydroxypyridine Succinate) and Placebo in Ischemic Stroke, sponsored by Pharmasoft. Completed at 17 sites in 3 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Pharmasoft · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 6 months after the study started (first participant enrolled Nov 2019, registered May 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Ischemic Stroke with a site in Russia — 12 open to participants now, 12 under way, 2 of them phase 3. Ischemic Stroke · Russia.

Started
2019
the only one that year
Phase 3
3 of 15
2 open now
Registered
6th of 15
by date
Lead sponsor
2 of 15
Pharmasoft

Among the 15 studies in Ischemic Stroke with a site in Russia, this one is the only one that started in 2019, is one of 3 in phase 3, and was the 6th registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

12 of the 15 studies in Ischemic Stroke with a site in Russia are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Ischemic Stroke with a site in Russia, or all of them as a file.
02

Study summary

The main purpose of the clinical trial is to evaluate the efficacy and safety of Mexidol® in sequential treatment for patients in the acute and early recovery periods of ischemic stroke compared to placebo. The effect of adding Mexidol® to standard therapy on the degree of impairment of vital functions was assessed including the degree of disability (according to the Modified Rankin Scale, mRS), the severity of neurological symptoms (according to the National Institutes of Health Stroke Scale, NIHSS) and the level of mobility of patients (according to the Rivermead Mobility Index).

Read the detailed description

As the main purpose of the clinical study is to evaluate safety and efficacy of a neuroprotector (Mexidol®), it was crucial to develop strict protocol requirements that would help to avoid the challenges of estimation of neuroprotective effect for stroke therapy. The current treatment options for stroke are still limited and do not take into account rehabilitation period and patients' further quality of life.

As per protocol requirements, 313 participants were screened, 304 participants met all comprehensive eligibility criteria, 25 participants dropped out during the clinical trial period. The Modified Rankin Scale (mRS) was selected as the most representative primary outcome measuring tool due to the adequate representation of functional outcome. Additionally, the neuroprotective efficacy of Mexidol® was assessed for its ability to reduce stroke-related neurologic deficit, to improve mobility after stroke and to influence cognitive impairment and mood disorder symptoms.

03

Conditions studied

  • Ischemic Stroke

Keywords

  • Stroke
  • Ischemic Stroke
  • Neuroprotective Agents
  • Antioxidants
  • Stroke Rehabilitation
  • Recovery of Function
  • Brain Ischemia
  • Acute Stroke
  • Acute Cerebrovascular Accident
  • Cerebral Stroke
  • Neuroprotection
  • Mexidol
  • Ethylmethylhydroxypyridine Succinate
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of first-ever hemispheric ischemic stroke (codes ICD-10: I63.0 - I63.9) with the time from onset of a stroke \<48 hours.
  • CT or MRI evidences of clinical diagnosis and no evidences of hemorrhagic stroke/hemorrhagic transformation of ischemic stroke.
  • The written form (ICF) is signed and personally dated by the participant or by an impartial witness (by a person who is independent of the trial and cannot be unduly influenced by the people involved with the trial and who attends the informed consent process).
  • The Modified Rankin Scale (mRS) score ≥3.
  • The National Institutes of Health Stroke Scale (NIHSS) score from 9 to 15 points.
  • Negative pregnancy test for women of childbearing age.
  • Willingness to use reliable methods of , and/or abstinence, for the duration of therapeutic product exposure.
  • The ability to understand the purpose of research, risks associated with the research intervention, obligations and consequences of research participation and their right of withdrawing consent any time during the study.

Exclusion criteria

Exclusion Criteria:

  • (Body Mass Index) > 35.
  • Recurrent or hemorrhagic stroke confirmed by CT/MRI.
  • Hemorrhagic transformation of ischemic stroke.
  • Parkinson's disease/parkinsonism.
  • Progressive Multiple Sclerosis.
  • Intractable Epilepsy.
  • Demyelinating diseases of central nervous system.
  • Hereditary and degenerative diseases of the central nervous system.
  • Infectious diseases of central nervous system in medical history.
  • Traumatic brain injury with severe neurocognitive impairment in medical history.
  • Congenital malformations of the nervous system or any neurological disorders that can affect participant's capability (including cognitive and motor skills) to follow protocol procedures.
  • Thrombolysis or thrombectomy treatment prior the enrollment.
  • Medical history of severe allergies.
  • Evidence of reactions or intolerance associated with ethylmethylhydroxypyridine.
  • Evidence of lactose intolerance, galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
  • Acute surgical pathology.
  • Evidence of first identified disorder or disease that can affect participant's ability to participate in the clinical trial.
  • Evidence of clinically significant severe disease/condition that can affect participant's ability to participate in the clinical trial: respiratory diseases, cardiovascular diseases (CVDs) including SAP ≥ 200 mm Hg and DAP ≥ 100 mm Hg, liver disease with elevation of /AST > 2 × , kidney disease (е\<30ml/min/1.73 m2), endocrine disorders and diseases, gastrointestinal diseases, pulmonary embolism (PE), deep vein thrombosis (DVT), floating thrombus, convulsive syndrome, uncontrolled hyperthermia, uncontrolled hyperglycemia.
  • Medical history of severe mental disorder.
  • Dementia of the Alzheimer type (DAT).
  • Medical history of cancers within 5 years prior to enrollment.
  • Medical history of alcohol/drug addiction.
  • Pregnancy or breastfeeding.
  • Prescription or use of prohibited medications within 2 weeks prior to enrollment.
  • Positive , syphilis, and C test.
  • Positive COVID-19 test.
  • Participation in another trial within 3 months prior to enrollment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
304 participants (actual)

Study arms

  • Experimental
    Mexidol®

    Participants received Mexidol® IV 500 mg 2 times a day for 10 days, then Mexidol® FORTE 250 orally 250 mg 1 tablet 3 times a day for 60 days

    Drug: Mexidol (Ethylmethylhydroxypyridine Succinate)

  • Placebo comparator
    Placebo

    Participants received Placebo matching Mexidol® IV 500 mg 2 times a day for 10 days, then Mexidol® FORTE 250 orally 250 mg 1 tablet 3 times a day for 60 days

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Modified Rankin Scale (mRS) Scores at the End of the Course of Therapy

    The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 0, Day 0-1 Scores).

    Time frame: Baseline, Day 71

Secondary outcomes

  1. Percentage of Subjects Having Modified Rankin Scale (mRS) Scores >3 (Higher Degree of Disability) at the End of the Course of Therapy

    The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\].

    Time frame: Day 71

  2. Percentage of Subjects Having Modified Rankin Scale (mRS) Scores 0-1 (Normal or Lower Degree of Disability) at the End of the Course of Therapy

    The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\].

    Time frame: Day 71

  3. Change From Baseline in the National Institutes of Health Stroke Scale (NIHSS) Score at the End of the Course of Therapy

    The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42 (severe stroke), with the minimum score being a 0 (no stroke symptoms) \[43 point scale: min value 0, max value 42, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 0, Day 0-1 Scores).

    Time frame: Baseline, Day 71

  4. Change From Baseline in the Rivermead Mobility Index (RMI) Score at the End of the Course of Therapy

    The Rivermead Mobility Index (RMI) is a hierarchical mobility scale used in neurological rehabilitation. It includes 15 items related to bed mobility, transfers, walking, stair use, and running. The test is comprised of 14 questions, and the patient is then asked to stand for 10 seconds without any aid. Each response is scored yes or no with 1 point for each yes answer. The scores are summed with a range from 0 (poor mobility) to 15 (excellent mobility) \[16 point scale: min value 0, max value 15, higher scores mean a better outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).

    Time frame: Baseline, Day 71

  5. Change From Baseline in the Montreal Cognitive Assessment (MoCA) Score at the End of the Course of Therapy

    The Montreal Cognitive Assessment (MoCA) is a 30-point validated scale that covers multiple cognitive domains including spatiotemporal orientation, sustained attention, visuospatial function, executive function, verbal memory, language, naming, and abstract thinking \[31 point scale: min value 0, max value 30, higher scores mean a better outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).

    Time frame: Baseline, Day 71

  6. Change From Baseline in the Hospital Anxiety and Depression Scale Score, Domain ANXIETY (HADS-A), at the End of the Course of Therapy

    The Hospital Anxiety and Depression Scale (HADS) is a brief self-report measure that was specifically designed to screen for distinct dimensions of anxiety and depression in nonpsychiatric hospital departments; somatic symptoms were excluded \[22 point scale for each domain (Anxiety or Depression): min value 0, max value 21, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).

    Time frame: Baseline, Day 71

  7. Change From Baseline in the Hospital Anxiety and Depression Scale Score, Domain DEPRESSION (HADS-D), at the End of the Course of Therapy

    The Hospital Anxiety and Depression Scale (HADS) is a brief self-report measure that was specifically designed to screen for distinct dimensions of anxiety and depression in nonpsychiatric hospital departments; somatic symptoms were excluded \[22 point scale for each domain (Anxiety or Depression): min value 0, max value 21, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).

    Time frame: Baseline, Day 71

07

Results

Posted Dec 8, 2025

Participant flow

Participant flow — Overall Study
MilestoneMexidol®Placebo
Started152152
Completed141138
Not completed1114

Outcome measures

PrimaryChange From Baseline in the Modified Rankin Scale (mRS) Scores at the End of the Course of Therapy

The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 0, Day 0-1 Scores).

Time frame:
Baseline, Day 71
Reported as:
Mean · score on a scale
Change From Baseline in the Modified Rankin Scale (mRS) Scores at the End of the Course of Therapy
score on a scaleMexidol®Placebo
Change From Baseline in the Modified Rankin Scale (mRS) Scores at the End of the Course of Therapy-2.45 (-2.70 to -2.23)-2.01 (-2.25 to -1.87)
SecondaryPercentage of Subjects Having Modified Rankin Scale (mRS) Scores >3 (Higher Degree of Disability) at the End of the Course of Therapy

The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\].

Time frame:
Day 71
Reported as:
Count of participants · Participants
Percentage of Subjects Having Modified Rankin Scale (mRS) Scores >3 (Higher Degree of Disability) at the End of the Course of Therapy
ParticipantsMexidol®Placebo
Percentage of Subjects Having Modified Rankin Scale (mRS) Scores >3 (Higher Degree of Disability) at the End of the Course of Therapy2239
SecondaryPercentage of Subjects Having Modified Rankin Scale (mRS) Scores 0-1 (Normal or Lower Degree of Disability) at the End of the Course of Therapy

The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke. Possible scores range from 0 (no symptoms at all) to 5 (dead) \[6 point scale: min value 0, max value 5, higher scores mean a worse outcome\].

Time frame:
Day 71
Reported as:
Count of participants · Participants
Percentage of Subjects Having Modified Rankin Scale (mRS) Scores 0-1 (Normal or Lower Degree of Disability) at the End of the Course of Therapy
ParticipantsMexidol®Placebo
Percentage of Subjects Having Modified Rankin Scale (mRS) Scores 0-1 (Normal or Lower Degree of Disability) at the End of the Course of Therapy8557
SecondaryChange From Baseline in the National Institutes of Health Stroke Scale (NIHSS) Score at the End of the Course of Therapy

The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42 (severe stroke), with the minimum score being a 0 (no stroke symptoms) \[43 point scale: min value 0, max value 42, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 0, Day 0-1 Scores).

Time frame:
Baseline, Day 71
Reported as:
Median · score on a scale
Change From Baseline in the National Institutes of Health Stroke Scale (NIHSS) Score at the End of the Course of Therapy
score on a scaleMexidol®Placebo
Change From Baseline in the National Institutes of Health Stroke Scale (NIHSS) Score at the End of the Course of Therapy-7 (-9 to -6)-7 (-8 to -5)
SecondaryChange From Baseline in the Rivermead Mobility Index (RMI) Score at the End of the Course of Therapy

The Rivermead Mobility Index (RMI) is a hierarchical mobility scale used in neurological rehabilitation. It includes 15 items related to bed mobility, transfers, walking, stair use, and running. The test is comprised of 14 questions, and the patient is then asked to stand for 10 seconds without any aid. Each response is scored yes or no with 1 point for each yes answer. The scores are summed with a range from 0 (poor mobility) to 15 (excellent mobility) \[16 point scale: min value 0, max value 15, higher scores mean a better outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).

Time frame:
Baseline, Day 71
Reported as:
Median · score on a scale
Change From Baseline in the Rivermead Mobility Index (RMI) Score at the End of the Course of Therapy
score on a scaleMexidol®Placebo
Change From Baseline in the Rivermead Mobility Index (RMI) Score at the End of the Course of Therapy10 (7 to 12)9 (7 to 11)
SecondaryChange From Baseline in the Montreal Cognitive Assessment (MoCA) Score at the End of the Course of Therapy

The Montreal Cognitive Assessment (MoCA) is a 30-point validated scale that covers multiple cognitive domains including spatiotemporal orientation, sustained attention, visuospatial function, executive function, verbal memory, language, naming, and abstract thinking \[31 point scale: min value 0, max value 30, higher scores mean a better outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).

Time frame:
Baseline, Day 71
Reported as:
Median · score on a scale
Change From Baseline in the Montreal Cognitive Assessment (MoCA) Score at the End of the Course of Therapy
score on a scaleMexidol®Placebo
Change From Baseline in the Montreal Cognitive Assessment (MoCA) Score at the End of the Course of Therapy4 (2 to 6)3 (1 to 6)
SecondaryChange From Baseline in the Hospital Anxiety and Depression Scale Score, Domain ANXIETY (HADS-A), at the End of the Course of Therapy

The Hospital Anxiety and Depression Scale (HADS) is a brief self-report measure that was specifically designed to screen for distinct dimensions of anxiety and depression in nonpsychiatric hospital departments; somatic symptoms were excluded \[22 point scale for each domain (Anxiety or Depression): min value 0, max value 21, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).

Time frame:
Baseline, Day 71
Reported as:
Median · score on a scale
Change From Baseline in the Hospital Anxiety and Depression Scale Score, Domain ANXIETY (HADS-A), at the End of the Course of Therapy
score on a scaleMexidol®Placebo
Change From Baseline in the Hospital Anxiety and Depression Scale Score, Domain ANXIETY (HADS-A), at the End of the Course of Therapy-2 (-5 to 0)-1 (-4 to 0)
SecondaryChange From Baseline in the Hospital Anxiety and Depression Scale Score, Domain DEPRESSION (HADS-D), at the End of the Course of Therapy

The Hospital Anxiety and Depression Scale (HADS) is a brief self-report measure that was specifically designed to screen for distinct dimensions of anxiety and depression in nonpsychiatric hospital departments; somatic symptoms were excluded \[22 point scale for each domain (Anxiety or Depression): min value 0, max value 21, higher scores mean a worse outcome\]. Change = (Visit 4, Day 71(+2) - Visit 1, Day 1 Scores).

Time frame:
Baseline, Day 71
Reported as:
Median · score on a scale
Change From Baseline in the Hospital Anxiety and Depression Scale Score, Domain DEPRESSION (HADS-D), at the End of the Course of Therapy
score on a scaleMexidol®Placebo
Change From Baseline in the Hospital Anxiety and Depression Scale Score, Domain DEPRESSION (HADS-D), at the End of the Course of Therapy-2 (-4 to 0)-1 (-4 to 0)

Adverse events

Collected over Throughout the study [From Day 1 up to Day 71]. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Mexidol®2/152 (1.3%)6/152 (3.9%)36/152 (23.7%)
Placebo1/152 (0.7%)4/152 (2.6%)39/152 (25.7%)
Most frequent serious events
Most frequent serious events
EventMexidol®Placebo
COVID-19Infections and infestations0/1523/152
PneumoniaInfections and infestations1/1520/152
Ischaemic strokeNervous system disorders1/1520/152
Brain oedemaNervous system disorders1/1520/152
Cerebral infarctionNervous system disorders1/1520/152
Pneumonia viralInfections and infestations1/1520/152
COVID-19 pneumoniaInfections and infestations1/1520/152
Cerebrovascular accidentNervous system disorders0/1521/152
Most frequent other events
Showing 10 of 42
Most frequent other events
EventMexidol®Placebo
Blood pressure increasedInvestigations3/1525/152
HeadacheNervous system disorders5/1522/152
TachycardiaCardiac disorders3/1524/152
COVID-19Infections and infestations3/1522/152
DiarrhoeaGastrointestinal disorders2/1521/152
Upper respiratory tract infectionInfections and infestations1/1522/152
Back painMusculoskeletal and connective tissue disorders2/1521/152
InsomniaPsychiatric disorders2/1520/152
Abdominal pain upperGastrointestinal disorders0/1521/152
ConstipationGastrointestinal disorders0/1521/152

Baseline characteristics

Age, Continuous
Age, Continuous(years)Mexidol®PlaceboTotal
Mean62.45 ± 7.8862.61 ± 7.4962.53 ± 7.68
Sex: Female, Male
Sex: Female, Male(Participants)Mexidol®PlaceboTotal
Female4852100
Male104100204
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Mexidol®PlaceboTotal
American Indian or Alaska Native000
Asian131629
Native Hawaiian or Other Pacific Islander000
Black or African American000
White139136275
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Mexidol®PlaceboTotal
Uzbekistan101020
Kazakhstan101020
Russia132132264
Modified Rankin Scale (mRS)
Modified Rankin Scale (mRS)(units on a scale)Mexidol®PlaceboTotal
Mean3.90 ± 0.503.94 ± 0.483.92 ± 0.49
Percentage of Subjects Having Modified Rankin Scale (mRS) Scores >3 (Higher Degree of Disability)
Percentage of Subjects Having Modified Rankin Scale (mRS) Scores >3 (Higher Degree of Disability)(Participants)Mexidol®PlaceboTotal
Count of participants152152304
Percentage of Subjects Having Modified Rankin Scale (mRS) Scores 0-1 (Normal or Lower Degree of Disa
Percentage of Subjects Having Modified Rankin Scale (mRS) Scores 0-1 (Normal or Lower Degree of Disa(Participants)Mexidol®PlaceboTotal
Count of participants000
National Institutes of Health Stroke Scale (NIHSS)
National Institutes of Health Stroke Scale (NIHSS)(units on a scale)Mexidol®PlaceboTotal
Median9 (9 to 11)10 (9 to 10)9.5 (9 to 10.5)

4 further baseline measures are reported on the registry.

08

Study locations

17 sites
  • Almaty City Hospital № 7
    Almaty, 050006, Kazakhstan
  • Kazan City Hospital № 7
    Kazan', 420103, Russia
  • Kemerovo City Clinical Hospital № 11
    Kemerovo, 650014, Russia
  • Research Institute - Regional Clinical Hospital № 1
    Krasnodar, 350086, Russia
  • Federal Center for Brain and Neurotechnology
    Moscow, 117997, Russia
  • Russian National Research Medical University n.a. N. I. Pirogov
    Moscow, 117997, Russia
  • Rostov State Medical University
    Rostov-on-Don, 344022, Russia
  • Alexandrovskaya Hospital
    Saint Petersburg, 193312, Russia
  • St. Petersburg Clinical Hospital № 26
    Saint Petersburg, 196247, Russia
  • City Hospital № 40 of Kurortny District
    Saint Petersburg, 197706, Russia
  • Samara Regional Clinical Hospital n.a. V. D. Seredavin
    Samara, 443095, Russia
  • Central Clinical Medical and Sanitary Unit n.a. V. A. Egorov
    Ulyanovsk, 432026, Russia
  • Voronezh Regional Clinical Hospital № 1
    Voronezh, 394066, Russia
  • Vsevolozhsk Clinical Interdistrict Hospital
    Vsevolozhsk, 188643, Russia
  • Yaroslavl Clinical Hospital № 2 (ICU)
    Yaroslavl, 150030, Russia
  • Yaroslavl Clinical Hospital № 2
    Yaroslavl, 150030, Russia
  • The first clinic of the Tashkent Medical Academy
    Tashkent, 100109, Uzbekistan
09

References and documents

Publications

  • Shamalov NA, Fedin AI, Rakhimbaeva GS, Nurguzhaev ES, Khasanova DR, Solovyova EY, Melnikova EV, Yanishevsky SN, Mashin VV, Pizova NV, Poverennova IE, Chuprina SE, Agafina AS, Roshkovskaya LV. [Results of the international multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of the sequential therapy with ethylmethylhydroxypyridine succinate in patients in the acute and early recovery periods of ischemic stroke (MIR)]. Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(8. Vyp. 2):40-53. doi: 10.17116/jnevro202512508240. Russian. PubMed 40898634 ↗
  • Koltsov IA, Shchukin IA, Fidler MS, Glukhareva AP, Chubykin VI. [Multimodal antioxidant therapy in ischemic stroke: from MIR trial to bedside]. Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(12. Vyp. 2):64-71. doi: 10.17116/jnevro202512512264. Russian. PubMed 41456191 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Aug 2023, 45 months.

Results were first posted in Dec 2025, 2 years 3 months after primary completion.

Of 165 phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's 45 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
May 31, 2024
StartActual
Nov 18, 2019
Primary completionActual
Aug 18, 2023
CompletionActual
Aug 18, 2023
Results first posted
Dec 8, 2025
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06437626
Lead sponsor
Pharmasoft
Responsible party
Sponsor
First posted
May 31, 2024
Start date
Nov 18, 2019
Primary completion
Aug 18, 2023
Completion
Aug 18, 2023
Results posted
Dec 8, 2025
Last update
Dec 30, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emoxypine succinate

Start the discussion